Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), filed a Form 4 on November 3, 2026, disclosing a share withholding transaction on October 30, 2026, related to the vesting of a restricted stock unit award.

Key Highlights

  • Reporting person: Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc.
  • Transaction date: October 30, 2026
  • Shares withheld: 9,540 shares of Common Stock disposed of (transaction code F) at $36.39 per share
  • Purpose of withholding: According to the filing, the shares were "withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award"
  • Beneficial ownership following transaction: 95,801 shares of Common Stock held directly

Pacira BioSciences CFO Share Withholding Details: October 30, 2026

According to the Form 4 filed with the SEC on November 3, 2026, Shawn Cross, the Chief Financial Officer of Pacira BioSciences, Inc., reported a single non-derivative securities transaction dated October 30, 2026. The transaction involved the disposition of 9,540 shares of Common Stock at a price of $36.39 per share under transaction code F, which denotes shares withheld by the issuer for tax purposes.

The filing states that the shares represent those "withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award." This type of transaction is a standard mechanism by which companies satisfy an employee's tax liability at the time restricted stock units vest, without requiring the individual to sell shares on the open market. No open-market sale was reported.

Following the reported transaction, Cross directly holds 95,801 shares of Pacira BioSciences Common Stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The form was signed by Kristen Williams as Attorney-in-Fact on November 3, 2026, and was filed as an individual, single-reporting-person submission.

What Was Disclosed

The filing disclosed that Pacira BioSciences CFO Shawn Cross had 9,540 shares of Common Stock withheld at $36.39 per share on October 30, 2026, to cover tax obligations on a vesting RSU award, leaving him with 95,801 directly held shares.